RESEARCH TRIANGLE PARK — Liquidia Technologies is another step closer to getting a patent for its hypertension drug.
The late-stage clinical biopharmaceutical company, which is focused on the development and commercialization of novel products using its proprietary PRINT technology, has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application related to LIQ861.
LIQ861 is the company’s proprietary dry powder treprostinil currently under review with the U.S. Food and Drug Administration (FDA) for the treatment of pulmonary arterial hypertension (PAH).
The patent is expected to cover methods of treating patients with pulmonary hypertension through the inhalation of dry powder treprostinil.
“The allowance of this patent will substantially strengthen and extend our intellectual property position with respect to dry powder inhaled treprostinil and represents an important milestone for LIQ861 on its path to potential commercialization,” said Neal Fowler, Liquidia’s CEO, in a statement.
“It also provides further evidence to support the novel advantages of our proprietary PRINT technology in therapeutic development. LIQ861 has the potential to address a significant unmet need for PAH patients seeking effective and convenient dosing of inhaled treprostinil. We are thrilled to have received this patent allowance for methods of treating patients with inhaled dry powder treprostinil, an essential step in creating value for our stockholders.”
A Notice of Allowance is issued after the USPTO determines that a patent should be granted from a patent application.
Liquidia said the patent is expected to be issued in the fourth quarter of 2020 and should have a term that expires no earlier than 2037.
After issuance, Liquidia said it plans to list the U.S. patent in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly referred to as the “Orange Book”, for LIQ861, if approved.